While the premium implant segment continues to offer significant growth potential, it accounts for just XX% of dental implants sold today. To open further growth opportunities, we began investing in non-premium brands in 2012 and have built an international portfolio, that includes the Neodent, Medentika, equinox, and Zinedent brands. In 2018, we extended it by acquiring Alpina in XX and by gaining control of T-Plus in Taiwan. The former strengthens our position in the intermediate-price range in Europe and in emerging markets like Russia and China. The latter gives us access to the fastgrowing third-tier segment in China and Taiwan. Both companies are well positioned for international growth, supported by the Group’s global network and expertise. They complement our implant portolio, which covers a broader price range in more countries than any other implant company.